Can dapagliflozin (Farxiga) be started in a patient with chronic kidney disease stage 3?

Yes, Farxiga (dapagliflozin) can be started in patients with CKD Stage 3.

Dapagliflozin is approved and strongly recommended for initiation in patients with CKD Stage 3, regardless of diabetes status, when the eGFR is ≥20 mL/min/1.73 m² 1. CKD Stage 3 encompasses eGFR 30-59 mL/min/1.73 m², which falls well within the approved initiation range.

Evidence-Based Initiation Criteria

The FDA-approved indication for dapagliflozin specifically includes reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with chronic kidney disease at risk of progression 1. The recommended dose is 10 mg once daily for kidney and cardiovascular protection 1.

Key Guideline Recommendations

Multiple high-quality guidelines from 2022-2025 strongly support SGLT2 inhibitor initiation in CKD Stage 3:

• KDIGO/ADA 2022 Consensus: Recommends SGLT2 inhibitors with proven kidney or cardiovascular benefit for patients with CKD and eGFR ≥20 mL/min/1.73 m² 2

• ADA 2022 Standards: Recommends SGLT2 inhibitors to reduce CKD progression and cardiovascular events in patients with eGFR ≥20 mL/min/1.73 m² and urine albumin ranging from normal to >200 mg/g creatinine 3

• KDOQI 2025: Strong recommendation supporting SGLT2 inhibitors as first-line agents for kidney and heart protection in those with eGFR ≥20 mL/min/1.73 m² 4

Clinical Trial Evidence

The landmark DAPA-CKD trial enrolled patients with eGFR 25-75 mL/min/1.73 m² (mean eGFR 43 mL/min/1.73 m²), demonstrating that dapagliflozin reduced the primary composite outcome (sustained ≥50% eGFR decline, ESKD, or renal/cardiovascular death) by 39% compared to placebo 5. This benefit was consistent regardless of diabetes status 6.

Importantly, 67.5% of DAPA-CKD participants had type 2 diabetes, while 32.5% had CKD without diabetes, proving efficacy across both populations 5.

Specific Considerations for CKD Stage 3

CKD Stage 3A (eGFR 45-59 mL/min/1.73 m²)

• Full approval for all indications: Both kidney protection AND glycemic control (if diabetic) 1
• The DERIVE study specifically demonstrated efficacy and safety in CKD Stage 3A patients 7
• No dose adjustment needed 2

CKD Stage 3B (eGFR 30-44 mL/min/1.73 m²)

• Approved for kidney and cardiovascular protection at 10 mg daily 1
• NOT recommended for glycemic control in this range, as glucose-lowering efficacy diminishes below eGFR 45 mL/min/1.73 m² 2, 1
• However, kidney and cardiovascular benefits are fully preserved 2

Expected eGFR Changes

A critical point for clinical practice: Expect an initial eGFR dip of 3-5 mL/min/1.73 m² within the first 4 weeks 4, 2. This is:

• Reversible and hemodynamically mediated (not kidney injury)
• Does NOT require drug discontinuation 2
• Typically stabilizes or returns toward baseline by 3 months 7
• Followed by long-term kidney protection with slower eGFR decline 5, 8

Risk Mitigation Strategies

Before initiating dapagliflozin in CKD Stage 3 patients 2:

Volume Status Assessment

• Correct volume depletion before starting
• Consider reducing diuretic doses in patients at risk for hypovolemia
• Monitor for orthostatic hypotension

Genital Hygiene Counseling

• Counsel on daily hygiene to prevent genital mycotic infections (occurs in ~6% vs 1% placebo) 2
• Women and uncircumcised men at higher risk 6

Sick Day Protocol

• Hold dapagliflozin during acute illness with nausea, vomiting, or diarrhea 4, 2
• Maintain at least low-dose insulin in insulin-requiring patients to prevent euglycemic ketoacidosis 2

Hypoglycemia Prevention

• Reduce insulin or sulfonylurea doses when initiating dapagliflozin if eGFR >45 mL/min/1.73 m² 2
• Below eGFR 45, glucose-lowering effect is minimal, so less adjustment needed

Monitoring After Initiation

• Recheck eGFR at 4 weeks to document the expected initial dip 4
• Continue therapy even if eGFR falls below 20 mL/min/1.73 m² after initiation, unless dialysis is started 2
• The DAPA-CKD and CREDENCE trials specifically allowed continuation below initiation thresholds 2

Common Pitfalls to Avoid

1. Don't withhold dapagliflozin due to the initial eGFR dip - this is expected and beneficial long-term 4, 2

2. Don't stop dapagliflozin if eGFR declines below 20 mL/min/1.73 m² after initiation - continue until dialysis 2

3. Don't expect significant glucose-lowering in CKD Stage 3B - the primary benefit is kidney and cardiovascular protection 2, 1

4. Don't forget to assess and optimize volume status first - particularly important in elderly patients 4, 2

Contraindications and Limitations

Dapagliflozin should NOT be initiated in 1:

• Polycystic kidney disease (not expected to be effective)
• Patients requiring or with recent immunosuppressive therapy for kidney disease
• Type 1 diabetes (for glycemic control indication)

Long-Term Benefits

Time-to-event analyses suggest that dapagliflozin may delay kidney failure by approximately 6.6 years in CKD populations similar to DAPA-CKD 8. Real-world evidence confirms these benefits extend to patients with lower albuminuria levels (<200 mg/g) 9, 10, supporting broad use across CKD Stage 3.

The evidence overwhelmingly supports initiating dapagliflozin 10 mg daily in CKD Stage 3 patients for kidney and cardiovascular protection, with the primary consideration being eGFR ≥20 mL/min/1.73 m² rather than specific CKD stage subdivisions 4, 2, 1.